Next Article in Journal
Cellular Metabolomics Revealed the Cytoprotection of Amentoflavone, a Natural Compound, in Lipopolysaccharide-Induced Injury of Human Umbilical Vein Endothelial Cells
Next Article in Special Issue
In Vitro Assessment of the Expression and T Cell Immunogenicity of the Tumor-Associated Antigens BORIS, MUC1, hTERT, MAGE-A3 and Sp17 in Uterine Cancer
Previous Article in Journal
Secondary Metabolites of the Endophytic Fungus Lachnum abnorme from Ardisia cornudentata
Previous Article in Special Issue
Restoration of Immune Responsiveness to Glioma by Vaccination of Mice with Established Brain Gliomas with a Semi-Allogeneic Vaccine
Article Menu
Issue 9 (September) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2016, 17(9), 1506; doi:10.3390/ijms17091506

Development of Novel Immunotherapies for Multiple Myeloma

1
Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226, USA
2
Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada
3
Department of Medicine, Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA
4
The Institute of Medical Sciences, University of Toronto, Toronto, ON M5S 1A8, Canada
5
Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226, USA
6
Cancer Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Xiaofeng Jia
Received: 14 July 2016 / Revised: 24 August 2016 / Accepted: 1 September 2016 / Published: 8 September 2016
View Full-Text   |   Download PDF [914 KB, uploaded 8 September 2016]   |  

Abstract

Multiple myeloma (MM) is a disorder of terminally differentiated plasma cells characterized by clonal expansion in the bone marrow (BM). It is the second-most common hematologic malignancy. Despite significant advances in therapeutic strategies, MM remains a predominantly incurable disease emphasizing the need for the development of new treatment regimens. Immunotherapy is a promising treatment modality to circumvent challenges in the management of MM. Many novel immunotherapy strategies, such as adoptive cell therapy and monoclonal antibodies, are currently under investigation in clinical trials, with some already demonstrating a positive impact on patient survival. In this review, we will summarize the current standards of care and discuss major new approaches in immunotherapy for MM. View Full-Text
Keywords: multiple myeloma; monoclonal antibodies; stem cell transplantation; CAR-T cell therapy multiple myeloma; monoclonal antibodies; stem cell transplantation; CAR-T cell therapy
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Al-Hujaily, E.M.; Oldham, R.A.A.; Hari, P.; Medin, J.A. Development of Novel Immunotherapies for Multiple Myeloma. Int. J. Mol. Sci. 2016, 17, 1506.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top